| Full text | |
| Author(s): |
Lima, Antonio Tiago
;
Amorim, Amanda Consulin
;
Britto-Junior, Jose
;
Campitelli, Raquel Rios
;
Fregonesi, Adriano
;
Monica, Fabiola Z.
;
Antunes, Edson
;
De Nucci, Gilberto
Total Authors: 8
|
| Document type: | Journal article |
| Source: | NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY; v. 395, n. 10, p. 12-pg., 2022-07-08. |
| Abstract | |
6-Nitrodopamine (6-ND) is an endogenous modulator of the contractility in the rat isolated epididymal vas deferens (RIEVD) and considered to be the main peripheral mediator of the emission process. Use of selective and unselective beta-adrenergic receptor antagonists has been associated with ejaculatory failure. Here, the effects of selective beta(1)- and beta(1)/beta(2)-adrenergic receptor antagonists on RIEVD contractions induced by 6-ND, dopamine, noradrenaline, adrenaline, and electric-field stimulation (EFS) were investigated. The selective beta(1)-adrenergic receptor antagonists atenolol (0.1 and 1 mu M), betaxolol (1 mu M), and metoprolol (1 mu M) and the unselective beta(1)/beta(2)-adrenergic receptor antagonists propranolol (1 and 10 mu M) and pindolol (10 mu M) caused significant rightward shifts of the concentration-response curve to 6-ND (pA(2) 6.41, 6.91, 6.75, 6.47, and 5.74; for atenolol, betaxolol, metoprolol, propranolol, and pindolol), but had no effect on dopamine-, noradrenaline-, and adrenaline-induced contractions. The effects of selective beta(1)- and beta(1)/beta(2)-adrenergic receptor antagonists at a higher concentration (atenolol 1 mu M, betaxolol 1 mu M, metoprolol 1 mu M, propranolol 10 mu M, and pindolol 10 mu M) also reduced the EFS-induced RIEVD contractions in control, but not in RIEVD obtained from L-NAME-treated animals. The selective beta(1)-adrenoceptor agonist RO-363, the selective beta(2)-adrenoceptor agonist salbutamol, and the selective beta(3)-adrenoceptor agonist mirabegron, up to 300 mu M, had no effect on the RIEVD tone. The results demonstrate that beta(1)- and beta(1)-/beta(2)-adrenoceptor receptor antagonists act as 6-ND receptor antagonists in RIEVD, further confirming the main role of 6-ND in the RIEVD contractility. (AU) | |
| FAPESP's process: | 21/14120-4 - Evaluation of adrenergic beta antagonists in the vas deferens duct in rats |
| Grantee: | Raquel Rios Campitelli |
| Support Opportunities: | Scholarships in Brazil - Scientific Initiation |
| FAPESP's process: | 19/16805-4 - Evaluation of the pathophysiological role of endothelial catecholamines |
| Grantee: | Gilberto de Nucci |
| Support Opportunities: | Research Projects - Thematic Grants |
| FAPESP's process: | 17/15175-1 - Modulation of soluble guanylate cyclase and the intracellular levels of cyclic nucleotides in the lower urinary tract and prostate |
| Grantee: | Edson Antunes |
| Support Opportunities: | Research Projects - Thematic Grants |
| FAPESP's process: | 21/13593-6 - Evaluation of chronic 6-nitrodopamine treatment in rats |
| Grantee: | Antonio Tiago Silva Lima |
| Support Opportunities: | Scholarships in Brazil - Doctorate (Direct) |